HK1 Cancer Research Results

HK1, Hexokinase 1: Click to Expand ⟱
Source:
Type:
Accelerated glucose metabolism is a common feature of cancer cells. Hexokinases catalyze the first committed step of glucose metabolism. HK1 (Hexokinase 1) is a key enzyme in glycolysis, catalyzing the phosphorylation of glucose to glucose-6-phosphate. It is critical for maintaining cellular energy homeostasis and is part of the metabolic reprogramming often observed in cancer cells.

• In some tumors, HK1 is upregulated to meet the high glycolytic demands of rapidly proliferating cancer cells. However, the expression pattern can be context-dependent, with some cancers potentially showing moderate or variable HK1 levels compared to the normal tissue counterpart.

• Enhanced HK1 expression supports the high glycolytic flux commonly seen in cancers (the Warburg effect), facilitating anabolic processes and thereby aiding in rapid cell proliferation and biomass accumulation.

• Changes in HK1 expression can also alter the balance between glycolysis and oxidative phosphorylation, potentially impacting reactive oxygen species (ROS) production and cellular redox status in tumors.
Scientific Papers found: Click to Expand⟱
2424- 2DG,  SRF,    The combination of the glycolysis inhibitor 2-DG and sorafenib can be effective against sorafenib-tolerant persister cancer cells
- in-vitro, HCC, Hep3B - in-vitro, HCC, HUH7
ChemoSen↓, Glycolysis↓, HK1↓, HK2↓, ATP↓,
206- Api,    Inhibition of glutamine utilization sensitizes lung cancer cells to apigenin-induced apoptosis resulting from metabolic and oxidative stress
- in-vitro, Lung, H1299 - in-vitro, Lung, H460 - in-vitro, Lung, A549 - in-vitro, CRC, HCT116 - in-vitro, Melanoma, A375 - in-vitro, Lung, H2030 - in-vitro, CRC, SW480
Glycolysis↓, lactateProd↓, PGK1↓, ALDOA↓, GLUT1↓, ENO1↓, ATP↓, Casp9↑, Casp3↑, cl‑PARP↑, PI3K/Akt↓, HK1↓, HK2↓, ROS↑, Apoptosis↑, eff↓, NADPH↓, PPP↓,
2289- Ba,  Rad,    Baicalein Inhibits the Progression and Promotes Radiosensitivity of Esophageal Squamous Cell Carcinoma by Targeting HIF-1A
- in-vitro, ESCC, KYSE150
TumCP↓, TumCMig↓, Glycolysis↓, cycD1/CCND1↓, CDK4↓, ECAR↓, TumCCA↑, HK1↓, ALDH↓, ALDOA↓, PKM2↓, Hif1a↓,
8384- LT,    Current situation and research progress of luteolin in the treatment of gastrointestinal malignant tumors
- Review, GC, NA
Apoptosis↑, TumAuto↑, TumCCA↑, EMT↓, *ROS↓, *antiOx↑, ROS↑, P53↑, LC3II↑, Beclin-1/ATG6↑, p‑MAP2K1/MEK1↓, p‑ERK↓, BAX↑, cl‑Casp3↑, Bcl-2↓, p‑MAPK↓, DNArepair↓, HMGB1↓, XRCC1↓, ERCC3↑, CycB/CCNB1↓, CDC2↓, p‑CHK1↑, TumCCA↑, TumCP?, Wnt↓, β-catenin/ZEB1↓, miR-384↑, PTN↓, MMP2↓, MMP3↓, MMP9↓, MMP16↓, Ferroptosis↑, GPx4↓, eff↑, Ki-67↓, GSH↓, ChemoSen↑, TumCP↓, TumCMig↓, TumCI↓, PI3K↓, Akt↓, mTOR↓, NF-kB↓, NOTCH↓, miR-139-5p↑, miR-34a↑, miR-422a↑, miR-107↑, miR-21↓, miR-155↓, miR-224↓, miR-340↓, E-cadherin↑, N-cadherin↓, Vim↓, HK1↓, FOXO1↓, compI↓, compIII↓, compV↓, ETC↓, BioAv↝,
2457- MET,    Metformin Impairs Glucose Consumption and Survival in Calu-1 Cells by Direct Inhibition of Hexokinase-II
- in-vitro, Lung, Calu-1
HK1↓, HK2↓, GlucoseCon↓, MMP↓, ATP↓,
2419- SK,    Regulation of glycolysis and the Warburg effect in wound healing
- in-vivo, Nor, NA
Glycolysis↓, GLUT1↓, GLUT3↓, HK2↓, HK1↓, PFK1↓, PFK2↓, PKM2↓, lactateProd↓, GlucoseCon↓,

Showing Research Papers: 1 to 6 of 6

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 6

Pathway results for Effect on Cancer / Diseased Cells:


NA, unassigned(tgid=0) ⓘ

compV↓, 1,   ERCC3↑, 1,   miR-107↑, 1,   miR-224↓, 1,   miR-422a↑, 1,   MMP16↓, 1,   PTN↓, 1,   XRCC1↓, 1,  

Redox & Oxidative Stress(tgid=1) ⓘ

compI↓, 1,   Ferroptosis↑, 1,   GPx4↓, 1,   GSH↓, 1,   HK1↓, 6,   ROS↑, 2,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

ATP↓, 3,   CDC2↓, 1,   compIII↓, 1,   ETC↓, 1,   MMP↓, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

ALDOA↓, 2,   ECAR↓, 1,   ENO1↓, 1,   GlucoseCon↓, 2,   Glycolysis↓, 4,   HK2↓, 4,   lactateProd↓, 2,   NADPH↓, 1,   PFK1↓, 1,   PFK2↓, 1,   PGK1↓, 1,   PI3K/Akt↓, 1,   PKM2↓, 2,   PPP↓, 1,  

Cell Death(tgid=5) ⓘ

Akt↓, 1,   Apoptosis↑, 2,   BAX↑, 1,   Bcl-2↓, 1,   Casp3↑, 1,   cl‑Casp3↑, 1,   Casp9↑, 1,   Ferroptosis↑, 1,   p‑MAPK↓, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

miR-21↓, 1,  

Autophagy & Lysosomes(tgid=9) ⓘ

Beclin-1/ATG6↑, 1,   LC3II↑, 1,   TumAuto↑, 1,  

DNA Damage & Repair(tgid=10) ⓘ

p‑CHK1↑, 1,   DNArepair↓, 1,   P53↑, 1,   cl‑PARP↑, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

CDK4↓, 1,   CycB/CCNB1↓, 1,   cycD1/CCND1↓, 1,   TumCCA↑, 3,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

ALDH↓, 1,   EMT↓, 1,   p‑ERK↓, 1,   FOXO1↓, 1,   p‑MAP2K1/MEK1↓, 1,   miR-34a↑, 1,   mTOR↓, 1,   NOTCH↓, 1,   PI3K↓, 1,   Wnt↓, 1,  

Migration(tgid=13) ⓘ

E-cadherin↑, 1,   Ki-67↓, 1,   miR-139-5p↑, 1,   miR-155↓, 1,   miR-340↓, 1,   miR-384↑, 1,   MMP2↓, 1,   MMP3↓, 1,   MMP9↓, 1,   N-cadherin↓, 1,   TumCI↓, 1,   TumCMig↓, 2,   TumCP?, 1,   TumCP↓, 2,   Vim↓, 1,   β-catenin/ZEB1↓, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

Hif1a↓, 1,  

Barriers & Transport(tgid=15) ⓘ

GLUT1↓, 2,   GLUT3↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

HMGB1↓, 1,   NF-kB↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↝, 1,   ChemoSen↓, 1,   ChemoSen↑, 1,   eff↓, 1,   eff↑, 1,  

Clinical Biomarkers(tgid=22) ⓘ

Ki-67↓, 1,  
Total Targets: 91

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 1,   ROS↓, 1,  
Total Targets: 2

Scientific Paper Hit Count for: HK1, Hexokinase 1
1 2-DeoxyGlucose
1 Sorafenib (brand name Nexavar)
1 Apigenin (mainly Parsley)
1 Baicalein
1 Radiotherapy/Radiation
1 Luteolin
1 Metformin
1 Shikonin
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:0  prod#:%  Target#:448  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page